NCT00630019已完成4 期
Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Santen Inc.
- 入组人数
- 96
- 试验地点
- 1
- 主要终点
- Concentration of levofloxacin and active control in the aqueous humor
研究概览
简要总结
Compare ocular tissue levels following topical ocular instillation of 1.5% levofloxacin ophthalmic solution or an active comparator in subjects undergoing cataract surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Capable of instilling eye drop
- •Scheduled for cataract surgery with intraocular lens (IOL) implantation
- •Be medically cleared for surgery
- •Women must be postmenopausal (for at least 1 year), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control before entry, and must agree to continue to use the same method of contraception throughout the study
- •Women of childbearing potential must have a negative urine pregnancy test at screening.
- •Willing to adhere to the prohibitions and restrictions specified in this protocol.
- •Subjects (or his/her legally acceptable representative) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
排除标准
- •Known allergy or other contraindication to the test article(s) or their components.
- •Presence of any abnormality or significant illness in the eye that in the investigator's opinion could affect the subject's health or the study parameters.
- •History of or presence of any corneal pathology or disease
- •Presence of an active ocular infection (bacterial, viral or fungal), or positive history of ocular herpetic infection.
- •History of severe dry eye syndrome.
- •History or evidence of previous ocular surgery in the operative eye.
- •History of any significant illness that could be expected to interfere with the study parameters.
- •Use of disallowed therapies (systemic or topical):
- •Fluoroquinolone anti-infective agents (systemic or topical) within 2 weeks of Visit 1 or anytime after Visit 1 for the duration of the study;
- •Topical ophthalmic preparations (including tear substitutes and rewetting drops), within 1 week of Visit 1 or anytime after Visit 1 for the duration of the study (other than the study medication as restricted above), with the exception of non-steroidal topical ophthalmic drops
- •Use of contact lenses in the 2 weeks prior to the study and for the duration of the study.
- •Received an experimental drug or used an experimental medical device within 30 days before the planned start of treatment.
- •Pregnant or breast-feeding.
- •Any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study.
- •Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.
研究组 & 干预措施
1
Experimental
干预措施: 1.5% levofloxacin ophthalmic solution (Drug)
2
Active Comparator
干预措施: 0.5% moxifloxacin hydrochloride ophthalmic solution (Drug)
结局指标
主要结局
Concentration of levofloxacin and active control in the aqueous humor
时间窗: Time of surgery
次要结局
- Adverse Events(4 days)
研究者
研究点 (1)
Loading locations...
相似试验
未知
4 期
Ophthalmic preoperative sterilization study of 1.5% LVFX ophthalmic solutioOphthalmic preoperative sterilizationJPRN-jRCT1080221649SANTEN PHARMACEUTICAL CO., LTD.100
Unknown
1 期
The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%EndophthalmitisNCT04214821National University of Malaysia128
终止
4 期
Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant SurgeryCorneal TransplantationNCT00764582Santen Inc.60
已完成
4 期
Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active ComparatorsHealthyNCT00703313Santen Inc.72
Unknown
1 期
The Clinical Safety of Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%Endophthalmitis PostoperativeNCT04212429National University of Malaysia128